摘要
如何延缓表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)获得性耐药已成为当前治疗非小细胞肺癌(NSCLC)的热点和难点。肿瘤干细胞(CSC)是肿瘤起始的关键细胞,CSC在EGFR-TKI耐药过程中也发挥了重要作用。初步研究发现中药能够抑制CSC特性延缓EGFR-TKI耐药,但具体分子机制尚不明确。本文通过梳理EGFR-TKI耐药的中医证治,结合近年来中药干预CSC延缓EGFR-TKI耐药的研究,探讨中药通过抑制CSC特性延缓EGFR-TKI耐药的可能相关分子通路及作用机制,以期拓展中医药联合靶向治疗的研究思路。
It has been popular and challenging to undertake researches on the delay of acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI).As key cells for tumor initiation,cancer stem cells(CSC)play an important role in the process of resistance to EGFR-TKI.Although preliminary studies found that traditional Chinese medicine(TCM)could inhibit CSC properties and delay EGFR-TKI resistance,the specific molecular mechanism remains unclear.By summarizing the empirical syndrome treatment of EGFR-TKI resistance via TCM and combining recent researches on TCM intervention in CSC to delay EGFR-TKI resistance,this review discussed the potential molecular pathways and mechanisms of deceleration in resistance to EGFR-TKI by TCM via inhibiting CSC characteristics,in order to expand the research ideas of TCM in combination with targeted therapy.
作者
刘磊
李振祥
李洋
王海永
林家茂
LIU Lei;LI Zhenxiang;LI Yang;WANG Haiyong;LIN Jiamao(Basic Teaching and Research Office of Traditional Chinese Medicine,College of Integrated Traditional Chinese and Western Medicine,Jining Medical University,Jining 272067;Department of Chest Radiotherapy,Shandong First Medical University Affiliated Cancer Hospital,Jinan 250117,China;Radioimmunoassay and Molecular Imaging Laboratory,Shandong First Medical University Affiliated Cancer Hospital,Jinan 250117,China;Department of Internal Medicine,Shandong First Medical University Affiliated Cancer Hospital,Jinan 250117,China;Department of Integrated Traditional Chinese and Western Medicine,Shandong First Medical University Affiliated Cancer Hospital,Jinan 250117,China)
出处
《细胞与分子免疫学杂志》
北大核心
2025年第1期77-82,共6页
Chinese Journal of Cellular and Molecular Immunology
基金
山东省自然科学基金创新发展联合基金项目(ZR2023LZY007)
山东省中医药重点学科建设项目(鲁卫中医药科教字[2022]4号)。
